Paclitaxel-coated balloon catheters reduce restenosis
This article has no abstract so we have provided the first paragraph of the full text.
The incidence of in-stent restenosis is still unacceptably high. Furthermore, the high rates of recurrence seen with current treatments for this condition highlight the need for new techniques. In animal studies, Scheller and co-workers found that intracoronary delivery of paclitaxel can produce antiproliferative effects and reduce neointimal formation. They therefore performed a double-blind pilot trial, randomizing 52 patients with in-stent restenosis to coronary angioplasty with either an uncoated or paclitaxel-coated balloon catheter.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
